ArticleThe Milbank quarterly2025
From Disappointment to Predominance: Medicare Advantage's Ascendancy and Transformation of Medicare.
Article in The Milbank quarterly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Opioid prescribing to older cancer survivors: a retrospective claims-based characterization of prescriber specialties.Journal of cancer survivorship : research and practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Policy Points Since 2004, beneficiaries in government-administered traditional Medicare decreased by about 3 million (8%), whereas enrollment in Medicare Advantage (MA) plans run by private insurance companies increased by approximately 30 million (500%). MA's growth has exceeded the adequate evolution and refinement of the program's regulatory apparatus. MA now annually costs at least 20% (around $84 billion) more than what Medicare would have spent if all MA enrollees were in traditional Medicare (TM). This differential in payments has advantaged MA relative to TM and transformed the Medicare program in part by corporatizing it for tens of millions of beneficiaries. Most MA revenue now flows to large, increasingly vertically integrated, multinational, for-profit companies that are reshaping the US health care landscape for all patients, providers, and payers. Overpayments have strengthened the political position of the largest MA plan providers such that the program is at risk of interest group capture because of their powerful lobbying and political influence. Reforming MA should include the following: (a) ongoing improvements to the program's risk adjustment system and benchmark policy for rate setting, (b) replacing the quality bonus program with a value incentive program that is budget-neutral, and (c) standardizing MA plans into a small number of basic plan categories and having private health companies make competitive bids in each of them to compete on price instead of on benefit offerings. Savings from any MA payment reforms could shore up Medicare's Hospital Trust Fund or improve TM for a "Medicare 2.0" that competes on a more level playing field with MA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.